Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.66 |
| ▸ | VDR | P11473 | 15/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12298778 | 0.88 | CYP24A1 (0.53) | CYP24A1VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL12298770 | 0.84 | CYP24A1 (0.48) | CYP24A1VDRHDAC6HDAC3 | |
| SCHEMBL12915642 | 0.82 | CYP24A1 (0.76) | CYP24A1VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL14351710 | 0.82 | CYP24A1 (0.76) | CYP24A1VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL14352042 | 0.82 | CYP24A1 (0.76) | CYP24A1VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL12298779 | 0.81 | CYP24A1 (0.46) | CYP24A1VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL14598180 | 0.81 | CYP24A1 (0.84) | CYP24A1VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL805084 | 0.81 | VDR (0.73) | CYP24A1VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL12408040 | 0.79 | CYP24A1 (1.00) | CYP24A1VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL12407981 | 0.79 | CYP24A1 (0.82) | CYP24A1VDRHDAC6HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026379-B2 | Paricalcitol intermediates | FORMOSA LABORATORIES, INC. (TW) | 2011-09-27 | — | — | US | disclosed |
| US-20090318722-A1 | PROCESS FOR PREPARATION OF PARICALCITOL INTERMEDIATES | FORMOSA LABORATORIES INC. (TW) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318722-A1 | PROCESS FOR PREPARATION OF PARICALCITOL INTERMEDIATES | CYP24A1, PTH1R, CYP2R1 | CYP24A1 1/4885VDR 9/4885HDAC6 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.